Expression analysis of inhibitory B7 family members in Alzheimer's disease.
Hani SabaieParham TamimiJalal GharesouranZoha SalkhordehMohammad Reza AsadiMirmohsen Sharifi-BonabZeinab Shirvani FarsaniMohammad TaheriArezou SayadMaryam RezazadehPublished in: Metabolic brain disease (2023)
Alzheimer's disease (AD) is a global health problem due to its complexity, which frequently makes the development of treatment methods extremely difficult. Therefore, new methodologies are necessary to investigate the pathophysiology of AD and to treat AD. The interaction of immune modulation and neurodegeneration has added new dimensions in current knowledge of AD etiology and offers an attractive opportunity for the discovery of novel biomarkers and therapies. Using quantitative polymerase chain reaction, we compared the expression levels of inhibitory B7 family members (B7-1, B7-2, B7-H1, B7-DC, B7-H3, B7-H4, B7-H5, B7-H7, and ILDR2), as immune regulators, in the peripheral blood of late-onset AD (LOAD) patients (n = 50) and healthy individuals (n = 50). The levels of B7-2, B7-H4, ILDR2, and B7-DC expression were significantly higher in-patient blood samples than in control blood samples. Furthermore, we discovered a substantial positive correlation between all gene expression levels. In addition, the current study indicated that ILDR2, B7-H4, B7-2, and B7-DC might serve as diagnostic biomarkers to identify LOAD patients from healthy persons. The present work provides additional evidence for the significance of inhibitory B7 family members to the etiology of LOAD.
Keyphrases
- gene expression
- late onset
- end stage renal disease
- ejection fraction
- newly diagnosed
- peripheral blood
- global health
- poor prognosis
- peritoneal dialysis
- healthcare
- dendritic cells
- early onset
- dna methylation
- small molecule
- immune response
- high resolution
- transcription factor
- high throughput
- mass spectrometry
- binding protein
- patient reported